HEALTHEURACTIV
Patents or patients? Two camps form over EU’s new pharma perks
The European Union's new pharmaceutical incentives have sparked a debate between industry groups seeking extended patent protections for nearly 30 drugs and advocates prioritizing patient access. Industry is requesting additional patent extensions for approximately 30 medications under the EU's new pharmaceutical policies.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
- Opinion: The innovation trap: How pharma weaponizes a word to extend monopolies
- STAT+: U.K. advocacy groups threaten court action over a key provision in the pharma trade deal with the U.S.
- Trump expands TrumpRx prescription drug discount program to more than 800 medications
- Trump expands TrumpRx prescription drug discount program to more than 800 medications